Nine Chapters Capital Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Nine Chapters Capital Management’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	$358K	Buy	105,500 +68,100	+182%	+$189K	0.79%	50
2017 Q2	$92K	Sell	37,400 -145,600	-80%	-$335K	0.87%	43
2017 Q1	$415K	Buy	183,000 +63,300	+53%	+$140K	0.56%	62
2016 Q4	$254K	Buy	119,700 +95,400	+393%	+$266K	0.43%	87
2016 Q3	$81K	Buy	+24,300	New	+$77.1K	0.57%	60
2015 Q4	–	Sell	-115,500	Closed	-$581K	–	925
2015 Q3	$581K	Buy	+115,500	New	+$662K	0.05%	521
2014 Q4	–	Sell	-22,000	Closed	-$164K	–	1372
2014 Q3	$164K	Buy	+22,000	New	+$204K	0.01%	879

Other funds holding PDLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Nine Chapters Capital Management's PDLI Position: Q3 2017 in Review

Nine Chapters Capital Management increased its PDL BioPharma, Inc. (PDLI) stake by 182% in Q3 2017, buying an estimated $189K and bringing the position to 105,500 shares worth $358K. The position accounts for 0.79% of the portfolio, ranked #50.

Nine Chapters Capital Management first reported a position in PDLI in Q3 2014 and has held it in 7 quarters since. The position peaked at $581K in Q3 2015. 186 funds tracked by Wall St. Rank hold PDLI as of Q3 2017.

Nine Chapters Capital Management held 105,500 shares of PDL BioPharma, Inc. worth $358K as of Q3 2017.
Nine Chapters Capital Management bought 68,100 PDL BioPharma, Inc. shares in Q3 2017, an estimated $189K.
PDL BioPharma, Inc. made up 0.79% of Nine Chapters Capital Management's portfolio in Q3 2017, its #50 holding.
Nine Chapters Capital Management first reported a position in PDL BioPharma, Inc. in Q3 2014 and has held it in 7 quarters since.
Nine Chapters Capital Management's PDL BioPharma, Inc. position peaked at $581K in Q3 2015.
186 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2017.

Based on Nine Chapters Capital Management's 13F filing for Q3 2017, filed 31 Oct 2017.